Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.82 +3.0%	$3.34	$2.70 ▼ $4.72	$711.20M	1.01	806,450 shs	2.65 million shs
ENTA Enanta Pharmaceuticals	$9.00 +7.1%	$7.69	$4.09 ▼ $13.37	$179.57M	0.84	137,887 shs	414,753 shs
NRIX Nurix Therapeutics	$9.11 -2.5%	$11.09	$8.18 ▼ $29.56	$714.04M	2.1	653,871 shs	1.23 million shs
OCS Oculis	$16.15 +0.1%	$18.00	$11.56 ▼ $23.08	$704.28M	0.26	10,096 shs	19,463 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+6.00%	+13.46%	+7.54%	-4.13%
ENTA Enanta Pharmaceuticals	0.00%	-3.00%	+18.14%	+16.83%	-34.78%
NRIX Nurix Therapeutics	0.00%	-3.41%	-15.40%	-22.68%	-62.94%
OCS Oculis	0.00%	-9.33%	-8.87%	-17.03%	+34.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.5766 of 5 stars	3.5	1.0	0.0	3.0	2.5	0.6
ENTA Enanta Pharmaceuticals	3.8164 of 5 stars	3.5	0.0	4.7	3.2	2.5	0.0
NRIX Nurix Therapeutics	2.5517 of 5 stars	4.4	1.0	0.0	3.0	0.8	0.0
OCS Oculis	2.4797 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	43.98% Upside
ENTA Enanta Pharmaceuticals	3.00	Buy	$22.25	147.22% Upside
NRIX Nurix Therapeutics	2.88	Moderate Buy	$28.87	216.87% Upside
OCS Oculis	3.00	Buy	$35.75	121.36% Upside

Current Analyst Ratings Breakdown

Latest ENTA, NRIX, ABUS, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	ENTA Enanta Pharmaceuticals	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
8/27/2025	OCS Oculis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
8/26/2025	NRIX Nurix Therapeutics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/22/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $33.00
8/12/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$24.00 ➝ $25.00
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/31/2025	NRIX Nurix Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$32.00 ➝ $30.00
7/28/2025	ENTA Enanta Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/15/2025	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $16.00
7/14/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $34.00
7/10/2025	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $26.00

(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	118.69	N/A	N/A	$0.43 per share	8.88
ENTA Enanta Pharmaceuticals	$67.64M	2.84	N/A	N/A	$3.71 per share	2.43
NRIX Nurix Therapeutics	$54.55M	12.77	N/A	N/A	$7.44 per share	1.22
OCS Oculis	$780K	903.99	N/A	N/A	$3.97 per share	4.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.32	N/A	N/A	N/A	-141.98%	-89.02%	-27.28%	N/A
NRIX Nurix Therapeutics	-$193.57M	-$2.61	N/A	N/A	N/A	-234.57%	-45.26%	-34.71%	10/10/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.67	N/A	N/A	N/A	-13,958.12%	-90.31%	-67.85%	11/6/2025 (Estimated)

Latest ENTA, NRIX, ABUS, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	OCS Oculis	-$0.53	-$0.59	-$0.06	-$0.59	$0.14 million	$0.25 million
8/11/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.25	-$0.85	+$0.40	-$0.85	$16.21 million	$18.31 million
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
7/9/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.79	-$0.52	+$0.27	-$0.52	$16.26 million	$44.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
ENTA Enanta Pharmaceuticals	N/A	5.00	5.00
NRIX Nurix Therapeutics	N/A	6.82	6.82
OCS Oculis	0.01	4.55	4.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ENTA Enanta Pharmaceuticals	94.99%
NRIX Nurix Therapeutics	N/A
OCS Oculis	22.30%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ENTA Enanta Pharmaceuticals	13.89%
NRIX Nurix Therapeutics	7.40%
OCS Oculis	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
NRIX Nurix Therapeutics	300	76.45 million	70.79 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable

ENTA, NRIX, ABUS, and OCS Headlines

Recent News About These Companies

Oculis Holding AG to Present Phase 2 ACUITY Trial Results for Privosegtor and Expanded Phase 3 DIAMOND Data at EURETINA Congress

September 1 at 4:10 AM | quiverquant.comQ

Oculis Holding AG to Present Phase 2 and Phase 3 Clinical Trial Results at EURETINA and Other Key Ophthalmology Conferences

September 1 at 4:10 AM | quiverquant.comQ

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

September 1 at 4:00 AM | globenewswire.com

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

September 1 at 4:00 AM | globenewswire.com

Oculis (NASDAQ:OCS) Coverage Initiated at Needham & Company LLC

August 29, 2025 | marketbeat.com

Oculis Holding AG Management to Participate in September Investor Conferences

August 28, 2025 | quiverquant.comQ

Oculis Holding AG to Participate in Notable Investor Conferences in September 2025

August 28, 2025 | quiverquant.comQ

Oculis to Participate in Upcoming September Investor Conferences

August 28, 2025 | globenewswire.com

Oculis to Participate in Upcoming September Investor Conferences

August 28, 2025 | globenewswire.com

Needham & Company LLC Initiates Coverage on Oculis (NASDAQ:OCS)

August 28, 2025 | americanbankingnews.com

Oculis initiated with a Buy at Needham

August 27, 2025 | msn.com

Oculis Holding AG $OCS Shares Bought by Pivotal bioVenture Partners Investment Advisor LLC

August 26, 2025 | marketbeat.com

Oculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology Respectively

August 25, 2025 | quiverquant.comQ

Oculis Holding AG Appoints Mark Kupersmith, M.D. and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisors to Lead Advances in Neuro-Ophthalmology and Ophthalmology

August 25, 2025 | quiverquant.comQ

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

August 25, 2025 | globenewswire.com

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

August 25, 2025 | globenewswire.com

Oculis (NASDAQ:OCS) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

August 24, 2025 | marketbeat.com

Oculis (NASDAQ:OCS) Price Target Raised to $33.00

August 24, 2025 | marketbeat.com

Oculis reports Q2 EPS (49c), consensus (43c)

August 23, 2025 | msn.com

Oculis Holding AG: Oculis Reports Q2 2025 Financial Results and Provides Company Update

August 22, 2025 | finanznachrichten.de

Oculis price target raised to $33 from $32 at H.C. Wainwright

August 22, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENTA, NRIX, ABUS, and OCS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.82 +0.11 (+2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$3.83 +0.01 (+0.26%)

As of 07:48 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Enanta Pharmaceuticals NASDAQ:ENTA

$9.00 +0.60 (+7.14%)

Closing price 04:00 PM Eastern

Extended Trading

$9.21 +0.21 (+2.38%)

As of 06:11 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$9.11 -0.23 (-2.46%)

Closing price 04:00 PM Eastern

Extended Trading

$9.28 +0.17 (+1.87%)

As of 07:13 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Oculis NASDAQ:OCS

$16.15 +0.02 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$16.04 -0.11 (-0.71%)

As of 04:10 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time